Innodata Inc vs Medpace Holdings Inc — how do they compare? Innodata Inc trades at $63.05 (market cap $2.03B), while Medpace Holdings Inc trades at $532.42 (market cap $15.08B). The key difference: Medpace Holdings Inc is far larger — about 7.4× Innodata Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Innodata Inc nearer its low. Which is the better fit depends on your goals.
| INOD | MEDP | |
|---|---|---|
Market Cap | $2.03B | $15.08B |
Sector | Technology | Technology |
52-Week High | $121.50 | $620.59 |
52-Week Low | $34.45 | $308.88 |
Enterprise Value | $1.91B | $14.55B |
Signals from Pluang's Aura AI — not financial advice
INOD trades at $62.08, up 2.09% today, showing strong momentum despite a bearish technical signal. The company demonstrates robust fundamentals with revenue growth from $252M in 2025 to $283M projected for 2026, and net income margins improving to 13.86%. Recent earnings beats and positive AI-driven news highlight growing demand for its engineering R&D services. Technical indicators show mixed signals with RSI suggesting oversold conditions but moving averages indicating bearish pressure.
Outlook remains positive with 60% analyst buy ratings and a $130 consensus price target representing 109% upside. Key opportunities include AI market expansion and customer diversification, while risks center on high valuation multiples (P/E 54.29) and customer concentration. The stock's recent 33% pullback may present a buying opportunity for growth-oriented investors.
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
Trailing returns across standard periods
Innodata is a global data engineering company that provides solutions for training AI models. It helps enterprises solve complex data challenges through high-quality data annotation and digital transformation.
Read more on INOD →Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →